• Shi Wu Wen, Qiuying Yang, Peter Garner, William Fraser, Olufemi Olatunbosun, Carl Nimrod, and Mark Walker.
• Department of Obstetrics and Gynecology, University of Ottawa Faculty of Medicine, Canada. swwen@ohri.ca
• Am. J. Obstet. Gynecol. 2006 Apr 1; 194 (4): 961-6.

ObjectiveThe purpose of this study was to assess the safety of the use of selective serotonin reuptake inhibitors in pregnancy.Study DesignWe carried out a retrospective cohort study of 972 pregnant women who had been given at least 1 selective serotonin reuptake inhibitor prescription in the year before delivery and 3878 pregnant women who did not receive selective serotonin reuptake inhibitors and who were matched by the year of the infant's birth, the type of institute at birth, and the mother's postal code from 1990 to 2000 in the Canadian province of Saskatchewan.ResultsThe risks of low birth weight (adjusted odds ratio, 1.58; 95% CI, 1.19, 2.11), preterm birth (adjusted odds ratio, 1.57; 95% CI, 1.28, 1.92), fetal death (adjusted odds ratio, 2.23; 95% CI, 1.01, 4.93), and seizures (adjusted odds ratio, 3.87; 95% CI, 1.00, 14.99) were increased in infants who were born to mothers who had received selective serotonin reuptake inhibitor therapy.ConclusionThe use of selective serotonin reuptake inhibitors in pregnancy may increase the risks of low birth weight, preterm birth, fetal death, and seizures.

11 keywords...

hide…